Report Categories
View AllRecent Articles
View All
VYNE Therapeutics Inc VYNE beats Q4 2025 EPS expectations significantly yet shares edge slightly lower in todays trading
Taysha TSHA Stock Treasury Trade Near Lows 20260416
Dermata DRMA Stock Valuation Dermata Therapeutics posts narrower loss 32 pct EPS beat
Affiliated MGRB Stock Value Opportunity Bearish Sentiment 20260416
OPTT Q1 2026 Earnings EPS Misses Estimates as Stock Rises Over 7
FRHC Q1 2026 Earnings Strong EPS Performance Despite Market Headwinds
NXST Q1 2026 Earnings EPS Surges Past Estimates on Strong Operational Performance
KLIC Q1 2026 Earnings EPS Surges Past Estimates as Semiconductor Demand Holds Steady
CSAI Q4 2025 Earnings Loss Widens Amid Transition Stock Falls 24